Endurant Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Endurant Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-13,768	Closed	-$303K	–	73
2019 Q4	$303K	Buy	+13,768	New	+$277K	0.1%	50
2018 Q1	–	Sell	-18,837	Closed	-$170K	–	88
2017 Q4	$170K	Buy	+18,837	New	+$139K	0.05%	75

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Endurant Capital Management's DRNA Position: Q1 2020 in Review

Endurant Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2020, closing a stake of 13,768 shares — an estimated $303K sold.

Endurant Capital Management first reported a position in DRNA in Q4 2017 and held it in 2 quarters. The position peaked at $303K in Q4 2019. 144 funds tracked by Wall St. Rank hold DRNA as of Q1 2020.

Endurant Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Endurant Capital Management sold 13,768 Dicerna Pharmaceuticals, Inc. shares in Q1 2020, an estimated $303K.
Endurant Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2017 and held it in 2 quarters.
Endurant Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $303K in Q4 2019.
144 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2020.

Based on Endurant Capital Management's 13F filing for Q1 2020, filed 15 May 2020.